Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers P > Headlines for Pharmion Corp. > News item |
Celgene, Pharmion merger clears waiting period hurdle
By Lisa Kerner
Charlotte, N.C., Jan. 3 - The Hart-Scott-Rodino waiting period has ended in the proposed merger of Celgene Corp. and Pharmion Corp., it was announced on Thursday.
It was previously reported that Celgene agreed to acquire Pharmion for $72 per share in a cash and stock transaction valued at $2.9 billion.
The companies expect the transaction to close in April, according to a news release.
Pharmion is an oncology company based in Boulder, Colo.
Celgene is a Summit, N.J., biopharmaceutical company.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.